Quick Answer
STERIS plc reported Research And Development Expense of $107.65 million for the year ending 2025.
- STERIS plc showed an increase of +3.8% in Research And Development Expense from 2024 to 2025.
- This data is from STERIS plc's annual report (Form 10-K), filed with the SEC on May 29, 2025.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $16.22 million | Q3 2018: $15.77 million | Q4 2018: $15.17 million | Q2 2019: $15.59 million | Q3 2019: $16.25 million | Q4 2019: $16.49 million | Q2 2020: $16.23 million | Q3 2020: $16.14 million | Q4 2020: $16.44 million | Q2 2021: $18.19 million | Q3 2021: $18.83 million | Q4 2021: $24.82 million | Q2 2022: $24.75 million | Q3 2022: $24.93 million | Q4 2022: $25.51 million | Q2 2023: $24.69 million | Q3 2023: $26.27 million | Q4 2023: $25.26 million | Q2 2024: $25.60 million | Q3 2024: $27.00 million | Q4 2024: $27.40 million | Q2 2025: $26.40 million | Q3 2025: $28.20 million | Q4 2025: $29.50 million.
- Over the full 9 years of available data (2017 to 2025), STERIS plc's Research And Development Expense has grown by 81.2%.
- Historical annual values: Fiscal year 2025: $107.65 million | Fiscal year 2024: $103.68 million | Fiscal year 2023: $98.48 million | Fiscal year 2022: $86.66 million | Fiscal year 2021: $66.33 million | Fiscal year 2020: $65.55 million | Fiscal year 2019: $63.04 million | Fiscal year 2018: $60.78 million | Fiscal year 2017: $59.40 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: